Брой 4/2022, Статии

Адалимумаб в лечението на Ювенилен идопатичен артрит – ефективност и имуногенност

Публикувана на от admin

Катя Темелкова¹, Маргарита Ганева¹, Теодор Василев¹, Калина Тумангелова-Юзеир² Екатерина Куртева², Георги Василев², Стефан Стефанов¹

¹Клиника по ревматология, кардиология и хематология, СБАЛДБ „проф. Иван Митев“, Медицински Университет, София
²Лаборатория по клинична имунология , УМБАЛ „Св.Иван Рилски“МУ, София

Резюме

През последните години беше постигнато значително подобрение в прогнозата на пациентите с ювенилен идиопатичен артрит, благодарение на навлизането в практиката на биологичните  медикаменти. Един от първите препарати, използван за контролиране на възпалителния процес и в България, е инхибитор на TNF-α – Адалимумаб. Събраните до момента данни доказват високата му ефективност и добра поносимост от пациентите. Представяме опита на клиника по Ревматология на СБАЛДБ при проследяване на 183 деца с ЮИА, провеждащи терапия с Адалимумаб. Изследване на терапевтично ниво и наличие на антитела към медикамента е следващата стъпка към индивидуализиране на терапията спрямо персоналните нужди на пациентите.

Ключови думи: Ювенилен идиопатичен  артрит; Биологични медикаменти; анти- TNF препарати ; анти –лекарствени антитела

To access this content, you must purchase Годишен абонамент.

Библиография

  1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007 Mar 3;369(9563):767-778..
  2. Petty RE, Southwood TR, Manners P et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390-2.
  3. Foster HE, Marshall N, Myers A et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003 Mar;48(3):767-75
  4. Nordal E, Zak M, Aalto K, Berntson L et al : Nordic Study Group of Pediatric Rheumatology. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011 Sep;63(9):2809-18..
  5. Consolaro A, Negro G, Lanni S et al Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S157-62
  6. Ruperto, N., Lovell, D., Reiff, A. et al. Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis. Pediatr Rheumatol 9 (Suppl 1), O26 (2011)  
  7. Kingsbury DJ, Bader-Meunier B, Patel G et al: Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433-41
  8. Brunner HI, Nanda K, Toth M et al: Paediatric Rheumatology International Trials Organisation, and the Pediatric Rheumatology Collaborative Study Group. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care Res (Hoboken). 2020 Oct;72(10):1420-1430.
  9. Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. Scand J Rheumatol. 2019 Mar;48(2):95-104.
  10. Tubach F, Salmon D, Ravaud P et al : Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009 Jul;60(7):1884-94.
  11. Lovell DJ, Ruperto N, Goodman S  et al : Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21359(8):810-20.
  12. Burmester GR, Panaccione R, Gordon KB et al : Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013 Apr;72(4):517-24.
  13. Wang J, Lozier J, Johnson G et al: Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008 Aug;26(8):901-8
  14. Pouw MF, Krieckaert CL, Nurmohamed MT et al: Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015 Mar;74(3):513-8.
  15. Strand V, Balsa A, Al-Saleh J et al: Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017 Aug;31(4):299-316.
  16. Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol. 2015;44(5):359-62.
  17. Murias S, Alcobendas R, Pascual-Salcedo D et al: Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience. Rheumatology (Oxford). 2014 Nov;53(11):2124-6.
  18. Nassar-Sheikh Rashid A, Schonenberg-Meinema D, Bergkamp SC et al: Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J. 2021 Apr 29;19(1):59.
  19. Marino A, Real-Fernández F, Rovero P et al: Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018 May;37(5):1407-1411.
  20. Vande Casteele N, Gils A, Singh S et al: Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun;108(6):962-71.

Адрес за кореспонденция:

Клиника по ревматология, кардиология и хематология, 

СБАЛДБ “проф. Иван Митев”,

Бул. “Aкад. Иван Гешов”, 15 

1431, София

e-mail: katiatem@gmail.com